Erasca, Inc.
Erasca, Inc. (ERAS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ERAS · as of Sep 30, 2025
Ownership Breakdown
146
Institutional Holders
▲ 2 vs Q2
$468.65M
Total Inst. Value
▲ $191.51M vs Q2
310.98M
Shares Outstanding
freeFloat 60.12%
214.97M
13F Shares Held
▼ 3.20M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ERAS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 22.73M | 8.02% | 8.02% | $49.55B | Nov 14, 2025 | — held |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 20.23M | 7.14% | 7.14% | $44.11B | Nov 14, 2025 | ▼ 100.3K |
VR ADVISER, LLC pharmaceutical preparations | 17.86M | 6.30% | 6.30% | $38.93B | Nov 14, 2025 | — held |
LOGOS GLOBAL MANAGEMENT LP pharmaceutical preparations | 15.15M | 5.35% | 5.35% | $33.03B | Nov 14, 2025 | ▲ 150.0K |
BLACKROCK, INC. pharmaceutical preparations | 15.07M | 5.32% | 5.32% | $32.86B | Nov 12, 2025 | ▼ 94.9K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 14.50M | 5.12% | 5.12% | $31.61B | Nov 14, 2025 | — held |
PARADIGM BIOCAPITAL ADVISORS LP pharmaceutical preparations | 13.56M | 4.79% | 4.79% | $29.56B | Nov 14, 2025 | ▲ 1.65M |
VANGUARD GROUP INC pharmaceutical preparations | 12.81M | 4.52% | 4.52% | $27.93B | Nov 7, 2025 | ▲ 116.2K |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 11.06M | 3.90% | 3.90% | $24.10B | Nov 14, 2025 | — held |
VIVO CAPITAL, LLC pharmaceutical preparations | 9.27M | 3.27% | 3.27% | $20.22B | Nov 14, 2025 | ▲ 2.52M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
20
Increased
+6.81M shares0
New Positions
first time holders16
Decreased
−5.68M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.13M
+6.81M / −5.68M
Net new holders
+4
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ERAS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
2
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Garner Ebun Chief Legal Officer | Apr 1, 2026 | Sale | 80,000 | $16.40 | $1.31M | 25.1K | Form 4 ↗ |
Morris Shannon Chief Medical Officer | Mar 4, 2026 | Sale | 20,000 | $15.04 | $300.8K | 0 | Form 4 ↗ |
Lim Jonathan E Chairman & CEO | Jan 29, 2026 | Award | 2,000,000 | $10.31 | $20.62M | 2.00M | Form 4 ↗ |
Chacko David M. CFO and CBO | Jan 29, 2026 | Award | 640,000 | $10.31 | $6.60M | 640.0K | Form 4 ↗ |
Chacko David M. CFO and CBO | Dec 15, 2025 | J-Other | 17,793 | $1.19 | $21.3K | 280.0K | Form 4 ↗ |
Morris Shannon Chief Medical Officer | Jan 29, 2026 | Award | 625,000 | $10.31 | $6.44M | 625.0K | Form 4 ↗ |
Varney Michael David director | Jan 29, 2026 | Award | 96,000 | $10.31 | $989.8K | 96.0K | Form 4 ↗ |
Garner Ebun General Counsel & Corp. Sec. | Jan 29, 2026 | Award | 560,000 | $10.31 | $5.77M | 560.0K | Form 4 ↗ |
Garner Ebun General Counsel & Corp. Sec. | Jan 7, 2026 | Sale | 120,000 | $5.59 | $670.8K | 25.1K | Form 4 ↗ |
Garner Ebun General Counsel & Corp. Sec. | Dec 15, 2025 | Award | 3,902 | $1.19 | $4.7K | 25.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Erasca, Inc. (ERAS) is primarily owned by institutional investors, who hold approximately 69.1% of total shares outstanding. Company insiders own approximately 39.88%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Erasca, Inc. is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding approximately 22.73 million shares — equal to 8.02% of outstanding shares — as of September 30, 2025.
A total of 146 institutional investors currently hold ERAS stock, with a combined institutional value of approximately $468,653,146 as of the most recent 13F filing period.
Frequently asked questions
ERAS ownershipErasca, Inc. (ERAS) is primarily owned by institutional investors, who hold approximately 69.1% of shares. The largest shareholder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with a 8.02% stake. Company insiders hold 39.88%. Data sourced from SEC Form 13F as of September 30, 2025.